Halifax-based Appili Therapeutics, a biopharmaceutical company developing drugs for infectious diseases, has added clinical research sites in Mexico and Brazil to its Phase 3 clinical trial evaluating favipiravir as a potential oral therapy for patients with mild-to-moderate COVID-19.
The expansion into Mexico and Brazil will ensure a timely completion of the trial, the company said in a statement.
There are more than 730 U.S. patients currently enrolled in the study. Appili expects to complete enrollment and report top-line results by the end of September.
“While the situation is